Barely Significant
← all excerpts

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis.

ACR Open Rheumatol · 2022 · PMC9661830 · PMID 36128663

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP < 0.001actually significant
In fact, the differences in the TIS between follow‐up visits in all subjects was highly significant ( P < 0.001), and in patients randomized to either tocilizumab or placebo, the pattern of scores showed a statistically significant improving trend in the TIS over the 24‐week trial period ( P < 0.02 for both arms).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.